Background: Acquired platelet function defects (PFDs) remain poorly characterized, underrecognized, and therefore understudied. Patients/Methods: Clinical and laboratory records of 109 patients with acquired PFDs diagnosed over 5 years were analyzed. Screening studies (platelet count, prothrombin time, activated partial thromboplastin time, and thrombin time), template bleeding time, platelet factor 3 (PF-3) availability test, light-transmission aggregometry, and further testing as indicated were performed. Results: 64 patients had mild and 26 had major bleeding. In all, 15 were referred for preoperative testing, whereas 4 had thrombotic events. Causes and associations of PFDs were drug-induced (34), idiopathic (34), hematopoietic neoplasms (15; myeloma 4, Waldenstrom macroglobulinemia 2, chronic myeloid leukemia 4, essential thrombocythaemia 3, and primary myelofibrosis and chronic lymphocytic leukemia 1 each), chronic liver disease (4), postcardiac surgery (2), uremia (2), and thalassemia major (7). Miscellaneous disorders comprised the rest. Conclusions: Acquired PFDs span a wide range of disease settings. Systematic, sequential laboratory testing identifies patterns of dysfunction, excludes inherited disorders, and streamlines management.
Introduction
Acquired bleeding disorders comprise a large proportion of referrals received in any hematology setup, more so among hospitalized patients. The number of patients with acquired bleeding disorders far exceeds those with inherited ones. Acquired bleeding disorders can occur because of platelet deficiency or dysfunction, deficiency or dysfunction of coagulation factors, or vascular structural abnormalities. 1, 2 Acquired defects of platelet function are believed to be extremely common clinically. Even so, the multifarious circumstances in which they may present, their varied associations as well as many practical difficulties in testing the platelet function make it difficult to systematically accrue and analyze data on these often enigmatic entities. 1, 2 This article presents data on acquired platelet function disorders, from a large general hospital setting in India.
Patients and Methods
The Hematology Department of this tertiary care hospital in northern India has clinical and laboratory sections. Both receive patients and referrals from all over the country as well as other departments. For this analysis, all the referrals received for bleeding or those specifically requesting platelet function studies for any reason were screened. Study data were tabulated retrospectively from departmental records, as chart review of the laboratory requests or clinical referrals over a 5-year period from January 1, 2004 to December 31, 2008. The patients evaluated included inpatients as well as outpatients.
Patients in whom bleeding was identified as occurring due to inherited causes were excluded. Identification of these inherited cases was done on the basis of clinical features, relevant family history (similarly affected members, consanguineous marriage), and available laboratory data. Clinical features suggesting inherited causes included early age of onset of bleeding; the nature, sites, and type of bleed; or history of excessive bleeding following trivial trauma, dental extraction, or minor surgical procedure from an early age.
Finally, only those patients with a likely acquired cause for bleeding associated with platelet dysfunction were selected after ensuring that there were no underlying familial/inherited bleeding present. If concomitant derangements were also present in the other hemostatic pathways, these were also characterized fully. The complete clinical and laboratory case records were tabulated and analyzed for these cases. Bleeding severity was graded per the World Health Organization (WHO) bleeding score. 3
Testing Methods
Platelet function testing followed a sequential approach in most cases that is outlined in Figure 1 .
A coagulation screen was first performed to exclude thrombocytopenia or coagulopathy as the cause of clinical abnormalities. Platelet count was performed using a Sysmex XT1800i automated analyzer (Sysmex Corp, Kobe, Japan) on EDTA anticoagulated blood. Prothrombin time (PT) using STA Neoplastine, partial thromboplastin time (PTT) by STA CK-Prest (cephalin reagent with kaolin activator), thrombin time (TT) by STA THROMBIN-2 (human calcium thrombin *1.5 NIH units/mL), and fibrinogen level using FIBRIPREST AUTO-MATE 2 kits (all from Diagnostica Stago, France) were estimated on platelet-poor plasma (PPP) separated from 4.5 mL blood in 0.5 mL 3.2% trisodium citrate dehydrate on a STA Compact automated hemostasis analyzer (Diagnostica Stago). D-dimer was assessed by the semiquantitative D-DI latex agglutination slide immunoassay, Diagnostica Stago, France.
For assessing the bleeding time (BT) using the template method, a standardized polystyrene template of length 11 mm was used with a scalpel blade to make an incision of 9 mm length and 1 mm depth on the volar aspect of the forearm, approximately 5 cm from the crease of the elbow, after cleaning the area and applying 40 mm Hg pressure using a sphygmomanometer cuff, avoiding superficial veins.
The Russel viper venom (RVV)-based platelet factor 3 (PF-3) availability tests (PF-3 release with adenosine diphosphate [ADP] at 0 and 20 minutes, total PF-3 assay) were used for screening inherited and acquired platelet dysfunction along with the BT. Briefly, PF-3 availability was measured by an RVV test on platelet-rich plasma (PRP), with the platelet count adjusted to 250 to 300 Â 10 9 /L. The patient's PRP was incubated with ADP (1 mmol/L) for 20 minutes and then the clotting time was measured after addition of RVV (20 mg/mL). The samples were run in triplicate and the average clotting time taken. If the variation in the individual test run was >1 second, the test was repeated. An age-and gender-matched control was run simultaneously. In our laboratory, the RVV time (RVVT) value for normal PF-3 availability ranges from 16.0 to 19.0 seconds (measured in individuals of both the genders) in patients with normal PT and activated PTT (APTT). 4, 5 Platelet aggregation studies with 50 mL of agonists including ADP (1.25 and 2.5 mL/mL), adrenalin (20 mL/mL), collagen (0.19 mg/mL), arachidonic acid (300 mmol/L), and ristocetin (1.2 mg/mL) were performed. Aggregation was monitored with Dual Channel Lumi-Aggregometer (Model 400, Chronolog Corporations Chicago) using 450 mL aliquots of PRP placed in cuvettes with a stir bar and warmed to 37 C. Maximal (100%) and baseline (0%) responses were set using PPP and PRP from the patients. 4, 5 For each different agonist concentration, the aggregation response was recorded and analyzed in duplicate and averaged. All measurements were completed within 2 hours from the blood draw.
In a small number of cases, further studies were required to fully characterize the platelet function defects (PFDs) or to ascertain the acquired and platelet-specific nature by excluding other disorders. These tests included human von Willebrand factor (vWF)-specific enzyme-linked immunosorbent assay (ELISA; Helena Laboratories, Beaumont, Texas), an in-house vWF-ristocetin cofactor assay using washed platelets 5 , flow cytometric determination of glycoprotein IIb (GP IIb) determination (BD FACSCanto flow cytometer, Becton Dickinson Biosciences, San Jose, CA, USA), and electron microscopy, where indicated.
Observations and Results
In the period between January 1, 2004 to December 31, 2008, a total of 6589 patients with various forms of bleeding were referred to the department. Of these, acquired platelet dysfunction was identified in 109 patients (1.7%). As depicted in Figure 1 . Diagnostic algorithm broadly used in most patients to detect suspected platelet dysfunction. The numbers of patients falling within each category are indicated, with some overlap. The dotted arrows indicate that some patients with major coagulation screendetected abnormalities were also investigated for platelet dysfunction if clinically warranted. BT indicates bleeding time; PF-3, platelet factor 3; PT, prothrombin time; aPTT, activated partial thromboplastin time; vWD, von Willebrand disease; RIPA, ristocetin-induced platelet aggregation; RiCOF, ristocetin cofactor assay; vFF Ag, von Willebrand factor antigen; FVIII, factor VIII; EM, electron microscopy; FCM, flow cytometry. Figure 1 , the patients selected for testing had to have either a significant family or past history of bleeding or a prolonged BT or PF-3 availability test for a complete platelet aggregometry to be performed. Those without any of these 3 entry criteria were tested once again if bleeding persisted and other diagnostic studies were negative. However, disease-specific research into platelet function in thalassemias, hemoglobinopathies, myeloproliferative neoplasms, cerebrovascular disease, and prothrombotic states was ongoing during these periods. The PFDs uncovered in these projects, also recorded in the same database, are included in these numbers, which may have skewed the findings.
The referrals for platelet function testing were received from all departments of the hospital, chiefly internal medicine and pediatrics, nephrology, obstetrics and gynecology, orthopedic surgery, cardiothoracic and vascular surgery, gastrosurgery/ gastroenterology, hematology and trauma, and intensive care and emergency medicine as well as from outside hospitals, chiefly in northern India. The age of the patients ranged from 2 years (Gaucher disease) to 78 years (primary myelofibrosis). Of the 109 patients, 59 (54.1%) were male.
Clinically, 90 (82.6%) patients presented with bleeding. Of these 90 patients, 64 had mild bleeding (71.1%, WHO grade 1/2), mostly skin bleeds, whereas 26 had major bleeding (28.9%, WHO grade 3/4). These included 4 intracranial bleeds (3 extradural hematomas and 1 subdural hematoma), 3 gastrointestinal tract bleeds, whereas most others were classified as major bleeding episodes on account of their requirement for blood transfusion specifically for blood loss. In all, 15 (13.8%) nonbleeding patients were referred for preoperative testing as they required surgery while on antiplatelet drugs. A total of 4 patients were referred for testing since they had had thrombotic events. All were, however, found as part of a separate study performed on 100 adult patients with stroke. Seven patients with thalassemia major were also found as part of a study evaluating the risk factors for thrombosis in thalassemia.
WHO grade 3 or 4 bleeding was seen most often in patients with systemic metabolic derangements (e.g. all 4 patients with liver disease and the 2 patients with end-stage renal disease) or in patients with serious co-morbidities (e.g. 3 hematological malignancies on therapy and in both the patients who were post-cardiac surgery). For the remainder of the patients, it was difficult to attribute any specific cause of PFD as having a greater propensity to severe bleeding, primarily due to the small numbers of individual cases in each group. In a few patients, clinicalÀlaboratory correlations were imperfect: subtle platelet aggregation abnormalities were seen in 2 patients with intracranial bleeds attributed to medications and 1 case of disseminated carcinoma colon with bleeding from the rectum. The contrary situation: florid platelet aggregation abnormalities with WHO grade 1 or 2 bleeding was seen in 12 patients, all with no clinically determined cause of bleeding.
The Table 1 .
The drugs found to be associated with the 34 patients with disorders of platelet function were aspirin (21 cases, 17 on low dose, 150 mg OD or less), thienopyridines (clopidogrel, ticlopidine; 4 cases), penicillin (2 cases), and 1 patient each, following exposure to halothane, chlorpromazine, losartan, atorvastatin, 4-drug antitubercular therapy (precise drug not identified), propanolol, and sodium valproate.
The BT was found to be prolonged in 31 (38.8%) of the 80 patients for whom results were available. The PF-3 availability test was positive in 58 (84%) of the 69 patients in whom testing was done. The aggregometric profiles of acquired platelet dysfunction are given in Table 2 . The commonest pattern seen was unclassified platelet dysfunction with an assortment of isolated findings of deranged PF-3 availability with normal subsequent testing, prolonged BT and PF-3 availability with normal subsequent testing, isolated diminished response to any 1 platelet agonist or combinations of abnormalities that did not fit any specific pattern. Although the number of causes was large and many were idiopathic, no significant pattern was noticed to correlate closely with a deranged BT or a deranged PF-3 availability or a combination thereof. Patients with any of the nonspecific abnormalities as well as with a defect in the coagulation pathways were excluded from the analysis.
Discussion
The current retrospective study, conducted over a 5-year period at a tertiary care referral department, revealed acquired PFDs spanning a heterogeneous range of clinical presentations with diverse etiological backgrounds and associations. This was in line with similar experiences in world literature reviews. 2, [6] [7] [8] Systematic study of acquired PFD is therefore of value to health care workers across multiple specialties. The management of acquired PFDs too differs from that of inherited forms since platelet transfusions are less likely to be effective in However, the identification of these disorders is beset by many problems. The clinicalÀlaboratory correlation is often imperfect in that many patients with significant laboratory abnormalities display only mild or minimal bleeding, whereas the significance of a deranged aggregometric response with a single agonist in a bleeding patient with multiple comorbidities and potential risk factors for bleeding is difficult to determine.
Light-transmission aggregometry is the commonest technique used to study platelet function worldwide. The method is, however, unreliable when the platelet counts in PRP are less than 100 Â 10 9 /L. 9 Our methodology may thus have excluded certain specific disorders where thrombocytopenia occurred in tandem with PFDs. These include relatively common conditions like immune thrombocytopenia, DIC (disseminated intravascular coagulation), and massive transfusion with stored blood. In our cases, the screening coagulogram indicating thrombocytopenia would have led to no further testing of platelet function, and our data will not represent true incidence of PFDs in these disorders.
A detailed clinical history and examination is the best screening test for bleeding disorders. 10 This is especially vital for platelet dysfunction where the underlying cause may be obscure or may be difficult to isolate from multiple physiological alterations in severely ill patients. 2, [6] [7] [8] However, it is generally acknowledged that a reliably predictive ''screening'' laboratory test for platelet dysfunction does not exist. [6] [7] [8] We used the BT and the PF-3 availability tests along with the clinical history to increase the sensitivity of PFD detection.
The BT, when performed in a stringently standardized manner, provides information on platelet number, function, and vessel wall integrity and is linked to the likelihood of bleeding during surgery or invasive procedures. However, extensive literature indicates that it alone has minimal clinical use. 11, 12 Although precise data is difficult to come by, it has been advocated as being significantly but variably prolonged in patients with a serious PFD but adequate platelet counts. 12 Platelet factor 3 is a platelet membrane phospholipid, which becomes available as a surface for coagulation reactions after platelet aggregation. Platelet factor 3 availability is decreased in a number of disorders of platelet function, including uremia. In our setting, with a preselected patient population with bleeding, these 2 tests taken together with the clinical background have a high sensitivity for inherited and acquired platelet dysfunction. 13, 14 They are, however, meant for screening alone, and further investigations, most notably vWD workup is necessary in all positive cases. 7, 8 Our methodology precluded the calculation of the specificity of the BT or the PF-3 availability, as the corresponding data on screen-positive but confirmatory investigation-negative patients was not collated.
Aspirin was the commonest cause of drug-induced platelet dysfunction in this study. The drug irreversibly inhibits the conversion of arachidonic acid to prostaglandins, especially thromboxane A 2 by platelet cyclooxygenase (COX-1 > COX-2). The platelet release reaction is thus inhibited within 15 to 30 minutes of ingestion of even 40 to 80 mg doses. Effects persist for the 8-to 10-day life span of the affected platelet. 7, 8, 15 Thienopyridines, however, noncompetitively inhibit ADP binding to its low-affinity P2Y12 receptor, resulting in uncoupling of the ADP receptor from GP IIb/IIIa with consequent impaired fibrinogen binding. 2, 7, 8, 15 Penicillins with an a-carboxy group adjacent to the b-lactam ring produce platelet dysfunction by modification of the platelet and megakaryocyte membrane, resulting in decreased agonist binding and decreased calcium influx. 2, [6] [7] [8] Quantitating aspirin effects is difficult and may be done by documenting either inhibition of platelet function or suppression of thromboxane A 2 production. 9 The former may be detected by the platelet function analyzer (PFA100) or by platelet aggregation responses; the latter may be detected by serum or urine II-dehydrothromboxane B 2 levels. [7] [8] [9] However, the clinical use of this assessment and the appropriate responses are not established.
The mechanisms underlying abnormal bleeding in the other major groups have also been elucidated. 2, [6] [7] [8] 16, 17 Abnormalities described in the myeloproliferative neoplasms include deficient lipid peroxidation and defective thromboxane A 2 responses, defective aggregation and release reaction, abnormal Fc receptor expression, subnormal serotonin uptake and storage as well as combined defects in activation and Table 2 . Aggregometric Patterns of Acquired Platelet Dysfunction Including Acquired von Willebrand Disease/syndrome (vWS) Unclassified in 63 (57.8%), commonest unclassified pattern was abnormal PF-3 availability with or without hypo-or absent aggregation with ADP and adrenaline (n ¼ 34, 31.2%) All 21 patients on aspirin showed impaired aggregation to epinephrine, ADP, and arachidonic acid with or without impaired agglutination with ristocetin Hyperaggregability in 10 (9.2%)-5 thalassemia major, 4 stroke, and 1 essential thrombocythemia Acquired vWS in 5 (4.6%)-2 gastrointestinal angiodysplasias, 1 multiple myeloma, 1 Waldenstrom macroglobulinemia, and 1 primary myelofibrosis Acquired storage pool defect in 2 (1.8%)-1 multiple myeloma and 1 chronic DIC; both confirmed on electron microscopy Abbreviations: ADP, adenosine diphosphate; PF-3, platelet factor 3; DIC, Disseminated intravascular coagulation. membrane expression of GP IIb/IIIa complexes. Also well characterized are acquired storage pool disorder and dysfunction due to the deficiency of high-molecular-weight multimers of plasma and platelet vWF in chronic myeloproliferative disorders. The latter results from enhanced proteolysis by ADAMTS13 of high-molecular-weight vWF that has uncoiled due to increased binding to platelets and high shear flow stresses. In the paraproteinemias, nonspecific binding of the immunoglobulins to the platelet surface has been implicated in the acquired dysfunction. 2, [6] [7] [8] 16, 17 An acquired hypercoagulable state with platelet hyperreactivity (and also endothelial activation, RBC membrane abnormalities, and altered coagulation protein levels) has been well described in patients with thalassemia. 7, 8, 16, 17 In addition, older articles found a relatively high incidence of hypoaggregability in vitro, although this did not translate into clinical bleeding. 17 Interestingly, Hussain et al postulated that this may be at least partially due to technical factors, since the preparation of PRP by separating the microcytic hypochromic RBCs requires longer centrifugation in these patients and may result in selective loss of metabolically active younger platelets. 17 Postsplenectomy thrombocytosis (all of our 7 patients were splenctomized), vitamin C and E deficiencies and iron overload may also play a role. 16, 17 Severe liver and renal disease with or without DIC are common causes of acquired PFDs, and several reviews cover the pathogenesis of platelet dysfunction in these conditions. 18, 19 In addition to the classic mechanisms of platelet dysfunction resulting in decreased function of the platelets, defects with gain-of-function abnormality are increasingly being recognized clinically. 20 The hyperactive platelet syndrome or sticky platelet syndrome is an uncommon entity that results in thrombosis of arterial or venous systems as well as pregnancy complications and otherwise. 20 Platelet function testing is not a part of the routine workup or screening for prothrombotic states and the 4 patients with stroke and the 5 patients having thalassemia major with hyperaggregability were uncovered as part of disease-focused research studies. Whether unprovoked arterial or venous thrombosis, especially in the young, should be investigated with platelet aggregometry is open to debate.
Other approaches and algorithms have been described for diagnosing PFDs. 7, 8 Despite variations in the tests used, the vital issue in all is convincingly establishing platelet-type bleeding and looking for an obvious underlying medical condition, a drug effect, or a previously undiagnosed vWD. In the event of a bleeding patient with abnormal platelet function tests without any clear-cut explanation, one author recommends clinical decision making to restrict itself to deciding whether platelet transfusions or desmopressin is required to restore pathologically compromised hemostasis or protect a patient with hemostatic risk. 7, 8 Conclusions Acquired PFDs necessitating laboratory evaluation span a wide range of clinical and biological settings as well as mechanistic patterns from virtually asymptomatic to ambulatory patients with drug-induced bleeding to inpatients with advanced medical or surgical illnesses. Idiopathic, drug-induced and malignancy-associated PFDs are most common in the setting evaluated, with an unclassified pattern commonest on laboratory testing. Optimal detection of acquired PFDs and exclusion of inherited disorders require detailed clinical inputs as well as a multiple laboratory tests. Systematic and sequential laboratory testing for acquired PFD identifies patterns of dysfunction, excludes inherited disorders, and streamlines further investigations and management.
